ACTN2

Across TCGA pan-cancer cohorts, ACTN2 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of ACTN2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where ACTN2 RNA is repressed in tumor relative to normal tissue. In most cancer types ACTN2 is over-expressed in tumor, although a few such as LUAD and LUSC show the opposite, repressed pattern.

LUAD, LUSC, and HNSC are the cancer types where ACTN2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ACTN2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	III,IV	−1.724	<.001	11	view →
LUSC	Male	III,IV	−2.165	<.001	9	view →
HNSC	Male	All	−2.644	.007	8	view →
LIHC	Male	All	+1.410	<.001	8	view →
BLCA	All	IV	−2.698	.012	6	view →
KIRC	All	III,IV	+0.417	.004	6	view →
STAD	All	All	−1.324	.003	5	view →
KICH	Female	All	−0.502	<.001	5	view →
BRCA	All	All	+0.464	.002	4	view →
KIRP	Male	All	−0.295	<.001	3	view →
PRAD	All	All	−1.074	.001	2	view →
THCA	All	II,III,IV	−0.462	.027	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

ACTN2–LUAD

Open the LUAD breakdown →